Study demonstrates potential of gene-editing T cells to treat liver cancer
27 November 2018
A recent study by the Maini group shows the potential of gene-editing liver resident T cells to treat hepatic tumors.
The study, led by the Maini Group and published in Molecular Therapy, demonstrates the potential of gene-editing PD-1 on TCR-redirected T cells for the treatment of liver cancer and viral infections.
Work on the paper, 'Molecular recalibration of PD-1+ antigen-specific T cells from blood and liver', was carried out by Itziar Otano who joined the Maini lab from Universidad de Navarra in Pamplona, Spain to work as a post-doc, funded by EASL and the Wellcome Trust.
For the final part of this project, Itziar worked in the labs of Andrea Pavesi and Antonio Bertoletti in Singapore to test genetically engineered T cells in their 3D microfluidic model of HBV-related liver cancer.
- Read the paper: Molecular recalibration of PD-1+ antigen-specific T cells from blood and liver (Molecular Therapy Journal)
- Maini Group
- Profile: Professor Mala Maini
- Transmission electron microscopic (TEM) image of hepatitis B virus (HBV) particles (orange) (Credit: CDC/ Dr. Erskine Palmer)